Miromatrix Medical Inc. (NASDAQ:MIRO) shares traded -35.22% lower at $1.60 on Wall Street last session.
In accordance with the data, 2 analysts cover Miromatrix Medical Inc. (NASDAQ:MIRO). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $18.00 and a low of $9.00, we find $13.50. Given the previous closing price of $2.47, this indicates a potential upside of 446.56 percent. MIRO stock price is now -46.64% away from the 50-day moving average and -54.29% away from the 200-day moving average. The market capitalization of the company currently stands at $35.36M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
It has been rated a hold by 0 analysts and a buy by 2. Brokers who have rated the stock have averaged $13.50 as their price target over the next twelve months.
.
Insiders disposed of 16,827 shares of company stock worth roughly $26923.2 over the past 1 year. A total of 2.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MIRO stock. A new stake in Miromatrix Medical Inc. shares was purchased by MAYO CLINIC during the first quarter worth $307,000. MERIT FINANCIAL GROUP, LLC invested $97,000 in shares of MIRO during the first quarter. In the first quarter, SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in Miromatrix Medical Inc. valued at approximately $32,000. HHM WEALTH ADVISORS, LLC acquired a new stake in MIRO for approximately $6,000. JPMORGAN CHASE & CO purchased a new stake in MIRO valued at around $3,000 in the second quarter. In total, there are 29 active investors with 17.00% ownership of the company’s stock.
Miromatrix Medical Inc. (NASDAQ: MIRO) opened at $1.4700 on Wednesday. During the past 12 months, Miromatrix Medical Inc. has had a low of $2.02 and a high of $5.29. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 8.10, and a quick ratio of 8.10. The fifty day moving average price for MIRO is $2.9987 and a two-hundred day moving average price translates $3.5006 for the stock.
The latest earnings results from Miromatrix Medical Inc. (NASDAQ: MIRO) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.37, beating analysts’ expectations of -$0.4 by 0.03. This compares to -$0.25 EPS in the same period last year. The company reported revenue of $12000.0 for the quarter, compared to $10000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 20.0 percent.
Miromatrix Medical Inc.(MIRO) Company Profile
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
